At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Rasburicase to Prevent Graft -Versus-Host Disease
In Brief
A Phase 1 clinical trial evaluating busulfan, cyclophosphamide, and 11 other interventions for Chronic Myeloproliferative Disorders and 6 related conditions. Completed, enrolled 46 participants across 1 site.
Detailed Summary
RATIONALE: Rasburicase may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying how well rasburicase works in preventing graft-versus-host disease in patients with hematologic cancer or other disease undergoing donor stem cell transplant.
Study Details
Timeline
Interventions
Busulfan 3.2 mg/kg/day from day -7 to day -4 as standard of care for myeloablative (bone marrow depletion) conditioning at the investigator's discretion
Cyclophosphamide as standard of care for myeloablative conditioning at the investigator's discretion
Cyclosporin-A as standard of care for GVHD prophylaxis at the investigator's discretion
Etoposide as standard of care for myeloablative conditioning at the investigator's discretion
Methotrexate 1.5 mg/kg/day on days -3, -2, and -1 as standard of care for GVHD prophylaxis at the investigator's discretion
Rasburicase 0.20 mg/kg intravenous infusion over 30 minutes for 5 to 7 days
Sirolimus as standard of care for GVHD prophylaxis at the investigator's discretion
Tacrolimus as standard of care for GVHD prophylaxis at the investigator's discretion
Total body irradiation 13.2 Gy over 8 fractions from day -7 to day - 4 for myeloablative conditioning at the investigator's discretion
Fludarabine 40 mg/m\^2/day from day -6 to day -3 as myeloablative conditioning at the investigator's discretion
Allopurinol per institutional guidelines